Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous adipose-derived mesenchymal stem cells for structural fecal incontinence
2010-021659-17Phase 2Completed
- Sponsor
- Andalusian Progress and Health Public Foundation
- Start
- May 2013
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of autologous adipose-derived mesenchymal stromal cells in fecal incontinence (FI) (2 arms), sponsored by Andalusian Progress and Health Public Foundation. Primary endpoints: Severity of incontinence, Fecal incontinence quality of life and 4 more. Started May 2013; status: completed.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
fecal incontinence (FI)
Beyond the preview
Go deeper on 2010-021659-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021659-17.